SAN
DIEGO, June 8, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, is scheduled to present and host investor
meetings at the Goldman Sachs 43rd Annual Global
Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022.
Details of the presentation are as follow:
Event:
|
|
|
|
Goldman Sachs
43rd Annual Global Healthcare Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, June 15,
2022
|
Presentation
Time:
|
|
|
|
8:00 a.m. PT / 11:00
a.m. ET
|
|
|
|
|
|
A live audio webcast of the presentation will be available in
the Investor Relations section of the Company's website. Replays of
the audio webcast will be available for 90 days following the
conference.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the delivery
of injected drugs and fluids in order to reduce the treatment
burden to patients. Having touched more than 600,000 patient lives
in post-marketing use in five commercialized products across more
than 100 global markets, Halozyme has licensed its ENHANZE®
technology to leading pharmaceutical and biotechnology companies
including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers
Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and
Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, novel therapeutic products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved safety and
efficacy, convenience, improved tolerability, and enhanced patient
comfort and adherence. The Company has a commercial portfolio of
proprietary products including XYOSTED®, TLANDO™ and NOCDURNA® and
partnered commercial products and ongoing product development
programs with industry leading pharmaceutical companies including
Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka
is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-goldman-sachs-43rd-annual-global-healthcare-conference-301563847.html
SOURCE Halozyme Therapeutics, Inc.